Listing 1 - 6 of 6 |
Sort by
|
Choose an application
Brucellosis, caused by the facultative intracellular bacteria Brucella species, is one the most prevalent zoonosis worldwide. • The articles described in this book report several aspects of host-Brucella interactions. • The findings described here will help to advance in the comprehension of bacterial pathogenesis and contribute to the future development of drugs or vaccines to control brucellosis.
Research & information: general --- Recombinant vaccine --- divalent vaccine --- brucellosis --- Omp25 --- L7/L12 --- Brucella abortus 544 --- ST2 receptor --- Brucella abortus --- oral infection --- human endometrial cells --- internalization --- intracellular replication --- decidualization --- chemokines --- macrophages --- Brucella --- HSC --- MHC --- IL-10 --- cell cycle --- (p)ppGpp --- rsh --- neurobrucellosis --- platelets --- brain microvascular endothelial cells --- endothelial cells --- adhesins --- Ig-like domain --- monomeric autotransporters --- trimeric autotransporters --- extracellular matrix --- polar localization --- virulence factors --- vaccine candidates --- fibronectin --- canonical inflammasome --- non-canonical inflammasome --- NLR --- pyroptosis --- ASC --- caspase-11 --- caspase-1 --- IL-1β --- gDNA --- replication niche --- reservoir --- persistence --- survival --- chronic infection --- n/a
Choose an application
Brucellosis, caused by the facultative intracellular bacteria Brucella species, is one the most prevalent zoonosis worldwide. • The articles described in this book report several aspects of host-Brucella interactions. • The findings described here will help to advance in the comprehension of bacterial pathogenesis and contribute to the future development of drugs or vaccines to control brucellosis.
Recombinant vaccine --- divalent vaccine --- brucellosis --- Omp25 --- L7/L12 --- Brucella abortus 544 --- ST2 receptor --- Brucella abortus --- oral infection --- human endometrial cells --- internalization --- intracellular replication --- decidualization --- chemokines --- macrophages --- Brucella --- HSC --- MHC --- IL-10 --- cell cycle --- (p)ppGpp --- rsh --- neurobrucellosis --- platelets --- brain microvascular endothelial cells --- endothelial cells --- adhesins --- Ig-like domain --- monomeric autotransporters --- trimeric autotransporters --- extracellular matrix --- polar localization --- virulence factors --- vaccine candidates --- fibronectin --- canonical inflammasome --- non-canonical inflammasome --- NLR --- pyroptosis --- ASC --- caspase-11 --- caspase-1 --- IL-1β --- gDNA --- replication niche --- reservoir --- persistence --- survival --- chronic infection --- n/a
Choose an application
Brucellosis, caused by the facultative intracellular bacteria Brucella species, is one the most prevalent zoonosis worldwide. • The articles described in this book report several aspects of host-Brucella interactions. • The findings described here will help to advance in the comprehension of bacterial pathogenesis and contribute to the future development of drugs or vaccines to control brucellosis.
Research & information: general --- Recombinant vaccine --- divalent vaccine --- brucellosis --- Omp25 --- L7/L12 --- Brucella abortus 544 --- ST2 receptor --- Brucella abortus --- oral infection --- human endometrial cells --- internalization --- intracellular replication --- decidualization --- chemokines --- macrophages --- Brucella --- HSC --- MHC --- IL-10 --- cell cycle --- (p)ppGpp --- rsh --- neurobrucellosis --- platelets --- brain microvascular endothelial cells --- endothelial cells --- adhesins --- Ig-like domain --- monomeric autotransporters --- trimeric autotransporters --- extracellular matrix --- polar localization --- virulence factors --- vaccine candidates --- fibronectin --- canonical inflammasome --- non-canonical inflammasome --- NLR --- pyroptosis --- ASC --- caspase-11 --- caspase-1 --- IL-1β --- gDNA --- replication niche --- reservoir --- persistence --- survival --- chronic infection
Choose an application
Since first receiving approval in 1986, antibody-based therapeutics have been the most successful modality for the treatment of various diseases. This Special Issue of IJMS, “Recent Advances in Antibody Therapeutics”, presents leading-edge articles and reviews for discovery, development, and clinical applications of therapeutic antibodies, covering antibody drug conjugates (ADCs), GPCR-targeting antibodies, a functional antibody screening, bioassay of bispecific antibodies, antibody applications for cardiovascular diseases, antibody delivery to CNS, etc. The excellent studies in this Special Issue would valuable insight for scientists and clinicians in the field of therapeutic antibodies
Research & information: general --- Chemistry --- interleukin 33 --- ST2 receptor --- scFv --- C2_2E12 --- bladder cancer --- antibodies --- immune checkpoint inhibitors --- antibody-drug conjugates --- sacituzumab govitecan --- enfortumab vedotin --- erdafitinib --- cost-effectiveness --- G protein-coupled receptor --- membrane protein --- antigen --- therapeutic antibody --- anti-angiogenesis --- delta-like ligand --- irinotecan --- paclitaxel --- VEGF --- SARS-CoV-2 --- spike protein --- receptor-binding domain --- phage display --- monoclonal antibody --- cytomegalovirus --- peptide/major histocompatibility complex class I complex --- T-cell-receptor-like antibody --- affinity maturation --- yeast surface display --- combinatorial antibody library --- agonist antibody --- cell fate --- bispecific antibodies --- bioassays --- mechanisms of action --- binding assays --- potency assays --- atherosclerosis --- inflammation --- antibody therapy --- blood–brain barrier --- antibody --- pharmacokinetics --- disposition --- biochemical and physicochemical properties --- Fc binding --- receptor-mediated transcytosis --- brain shuttle --- molecular Trojan horse --- transferrin --- anti-cancer antibody --- antibody engineering --- biophysical properties --- computational methods --- research cell bank --- antibody therapeutics --- recombinant antibodies --- intracellular antibodies --- single-chain antibody fragment --- nanobody --- Human papillomaviruses --- HPV oncoproteins --- HPV-associated cancer --- HPV cancer therapy --- asthma --- refractory asthma --- biomarker --- n/a --- blood-brain barrier
Choose an application
Since first receiving approval in 1986, antibody-based therapeutics have been the most successful modality for the treatment of various diseases. This Special Issue of IJMS, “Recent Advances in Antibody Therapeutics”, presents leading-edge articles and reviews for discovery, development, and clinical applications of therapeutic antibodies, covering antibody drug conjugates (ADCs), GPCR-targeting antibodies, a functional antibody screening, bioassay of bispecific antibodies, antibody applications for cardiovascular diseases, antibody delivery to CNS, etc. The excellent studies in this Special Issue would valuable insight for scientists and clinicians in the field of therapeutic antibodies
interleukin 33 --- ST2 receptor --- scFv --- C2_2E12 --- bladder cancer --- antibodies --- immune checkpoint inhibitors --- antibody-drug conjugates --- sacituzumab govitecan --- enfortumab vedotin --- erdafitinib --- cost-effectiveness --- G protein-coupled receptor --- membrane protein --- antigen --- therapeutic antibody --- anti-angiogenesis --- delta-like ligand --- irinotecan --- paclitaxel --- VEGF --- SARS-CoV-2 --- spike protein --- receptor-binding domain --- phage display --- monoclonal antibody --- cytomegalovirus --- peptide/major histocompatibility complex class I complex --- T-cell-receptor-like antibody --- affinity maturation --- yeast surface display --- combinatorial antibody library --- agonist antibody --- cell fate --- bispecific antibodies --- bioassays --- mechanisms of action --- binding assays --- potency assays --- atherosclerosis --- inflammation --- antibody therapy --- blood–brain barrier --- antibody --- pharmacokinetics --- disposition --- biochemical and physicochemical properties --- Fc binding --- receptor-mediated transcytosis --- brain shuttle --- molecular Trojan horse --- transferrin --- anti-cancer antibody --- antibody engineering --- biophysical properties --- computational methods --- research cell bank --- antibody therapeutics --- recombinant antibodies --- intracellular antibodies --- single-chain antibody fragment --- nanobody --- Human papillomaviruses --- HPV oncoproteins --- HPV-associated cancer --- HPV cancer therapy --- asthma --- refractory asthma --- biomarker --- n/a --- blood-brain barrier
Choose an application
Since first receiving approval in 1986, antibody-based therapeutics have been the most successful modality for the treatment of various diseases. This Special Issue of IJMS, “Recent Advances in Antibody Therapeutics”, presents leading-edge articles and reviews for discovery, development, and clinical applications of therapeutic antibodies, covering antibody drug conjugates (ADCs), GPCR-targeting antibodies, a functional antibody screening, bioassay of bispecific antibodies, antibody applications for cardiovascular diseases, antibody delivery to CNS, etc. The excellent studies in this Special Issue would valuable insight for scientists and clinicians in the field of therapeutic antibodies
Research & information: general --- Chemistry --- interleukin 33 --- ST2 receptor --- scFv --- C2_2E12 --- bladder cancer --- antibodies --- immune checkpoint inhibitors --- antibody-drug conjugates --- sacituzumab govitecan --- enfortumab vedotin --- erdafitinib --- cost-effectiveness --- G protein-coupled receptor --- membrane protein --- antigen --- therapeutic antibody --- anti-angiogenesis --- delta-like ligand --- irinotecan --- paclitaxel --- VEGF --- SARS-CoV-2 --- spike protein --- receptor-binding domain --- phage display --- monoclonal antibody --- cytomegalovirus --- peptide/major histocompatibility complex class I complex --- T-cell-receptor-like antibody --- affinity maturation --- yeast surface display --- combinatorial antibody library --- agonist antibody --- cell fate --- bispecific antibodies --- bioassays --- mechanisms of action --- binding assays --- potency assays --- atherosclerosis --- inflammation --- antibody therapy --- blood-brain barrier --- antibody --- pharmacokinetics --- disposition --- biochemical and physicochemical properties --- Fc binding --- receptor-mediated transcytosis --- brain shuttle --- molecular Trojan horse --- transferrin --- anti-cancer antibody --- antibody engineering --- biophysical properties --- computational methods --- research cell bank --- antibody therapeutics --- recombinant antibodies --- intracellular antibodies --- single-chain antibody fragment --- nanobody --- Human papillomaviruses --- HPV oncoproteins --- HPV-associated cancer --- HPV cancer therapy --- asthma --- refractory asthma --- biomarker
Listing 1 - 6 of 6 |
Sort by
|